SHR2554 Plus Liposomal Mitoxantrone as First-line Treatment for Peripheral T-cell Lymphoma (PTCL)
NCT07725705
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
NOT_YET_RECRUITING
Status
44
Enrollment
OTHER
Sponsor class
Conditions
PTCL
First Line Treatment
Interventions
DRUG:
SHR2554 combined with Liposomal Mitoxantrone
Sponsor
Institute of Hematology & Blood Diseases Hospital, China